Example of Hematology Reports  format
Recent searches

Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format Example of Hematology Reports  format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Hematology Reports — Template for authors

Categories Rank Trend in last 3 yrs
Hematology #91 of 123 up up by 1 rank
journal-quality-icon Journal quality:
Medium
calendar-icon Last 4 years overview: 111 Published Papers | 159 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 11/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Nature

Quality:  
High
CiteRatio: 16.0
SJR: 4.539
SNIP: 2.28
open access Open Access

Springer

Quality:  
High
CiteRatio: 4.6
SJR: 1.06
SNIP: 1.301
open access Open Access

Springer

Quality:  
High
CiteRatio: 6.3
SJR: 1.037
SNIP: 0.989
open access Open Access

Elsevier

Quality:  
High
CiteRatio: 7.2
SJR: 1.638
SNIP: 0.997

Journal Performance & Insights

CiteRatio

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

A measure of average citations received per peer-reviewed paper published in the journal.

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.4

8% from 2019

CiteRatio for Hematology Reports from 2016 - 2020
Year Value
2020 1.4
2019 1.3
2018 1.7
2017 1.4
2016 1.0
graph view Graph view
table view Table view

0.239

4% from 2019

SJR for Hematology Reports from 2016 - 2020
Year Value
2020 0.239
2019 0.229
2018 0.349
2017 0.385
2016 0.288
graph view Graph view
table view Table view

0.41

1% from 2019

SNIP for Hematology Reports from 2016 - 2020
Year Value
2020 0.41
2019 0.414
2018 0.577
2017 0.825
2016 0.381
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has increased by 8% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

insights Insights

  • SJR of this journal has increased by 4% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has decreased by 1% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Hematology Reports

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

PagePress Publications

Hematology Reports

Approved by publishing and review experts on SciSpace, this template is built as per for Hematology Reports formatting guidelines as mentioned in PagePress Publications author instructions. The current version was created on 11 Jul 2020 and has been used by 831 authors to write and format their manuscripts to this journal.

Hematology

Medicine

i
Last updated on
11 Jul 2020
i
ISSN
2038-8322
i
Impact Factor
Low - 0.339
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
Vancouver
i
Citation Type
Numbered (Superscripted)
25
i
Bibliography Example
Blonder GE, Tinkham M, Klapwijk TM. Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent con-version. Phys Rev B. 1982;25(7):4515–4532. Available from: 10.1103/PhysRevB.25.4515.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.4081/HR.2015.5844
The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis
Matthew Y. Wei1, Salena M Ward1
23 Nov 2015 - Hematology Reviews

Abstract:

Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifying the presence of Anti-factor Xa (AFXa) for dose adjustment. However, currently there are no guidelines for LM... Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifying the presence of Anti-factor Xa (AFXa) for dose adjustment. However, currently there are no guidelines for LMWH monitoring in patients on thromboprophylactic, doses, despite certain patient populations may be at risk of suboptimal dosing. This review found that while the AFXa ranges for therapeutic levels of LMWHs are relatively well defined in the literature, prophylactic ranges are much less clear, thus making it difficult to interpret current research data. From the studies published to date, we concluded that a reasonable AFXa target range for LMWH deep venous thromboses prophylaxis might be 0.2-0.5 IU/mL. read more read less

Topics:

Low molecular weight heparin (54%)54% related to the paper
View PDF
100 Citations
open accessOpen access Journal Article DOI: 10.4081/HR.2010.E2
Pathological basis of symptoms and crises in sickle cell disorder: implications for counseling and psychotherapy
Oluwatoyin Olatundun Ilesanmi1
13 Apr 2010 - Hematology Reviews

Abstract:

Sickle Cell Disorder (SCD) is a congenital hemoglobinopathy. There is little in literature regarding the psychological variables affecting individuals living with SCD and all of the significant people around them. There are also limited numbers of trained clinical psychologists and genetic counselors to cater for the psychoth... Sickle Cell Disorder (SCD) is a congenital hemoglobinopathy. There is little in literature regarding the psychological variables affecting individuals living with SCD and all of the significant people around them. There are also limited numbers of trained clinical psychologists and genetic counselors to cater for the psychotherapeutic needs of individuals living with SCD. Even among those who have been trained, only a few might have fully grasped the complexities of the disease pathology. Early understanding of its pathological nature, sources, types, complications, pathophysiological basis, and clinical severity of symptoms among clinical psychologists, genetic counselors and psychotherapists, as well as general medical practitioners, could guide them in providing holistic care for dealing with and reducing pain among individuals living with SCD. It could allow risk-based counseling for families and individuals. It could also justify the early use of disease-modifying or curative interventions, such as hydroxyurea (HU), chronic transfusions (CTs), or stem-cell transplantation (SCT) by general medical practitioners. Hence, the need for this paper on the pathophysiology of SCD. read more read less

Topics:

Genetic counseling (53%)53% related to the paper, Transplantation (52%)52% related to the paper, Disease (50%)50% related to the paper
View PDF
67 Citations
open accessOpen access Journal Article DOI: 10.4081/HR.2017.7053
Atypical Hemolytic Uremic Syndrome: A Brief Review.
Kuixing Zhang1, Yuxin Lu2, Kevin Harley2, Minh-Ha Tran2
01 Jun 2017 - Hematology Reviews

Abstract:

Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury The histopathologic lesions of aHUS include thrombotic microangiopathy involving the glomerular capillaries and thrombosis involving arterioles or interlobar arteries... Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury The histopathologic lesions of aHUS include thrombotic microangiopathy involving the glomerular capillaries and thrombosis involving arterioles or interlobar arteries Extra-renal manifestations occur in up to 20% of patients The majority of aHUS is caused by complement system defects impairing ordinary regulatory mechanisms Activating events therefore lead to unbridled, ongoing complement activity producing widespread endothelial injury Pathologic mutations include those resulting in loss-of-function in a complement regulatory gene (CFH, CFI, CD46 or THBD) or gain-of-function in an effector gene (CFB or C3) Treatment with the late complement inhibitor, eculizumab - a monoclonal antibody directed against C5 - is effective read more read less

Topics:

Atypical hemolytic uremic syndrome (73%)73% related to the paper, Eculizumab (66%)66% related to the paper, Thrombotic microangiopathy (65%)65% related to the paper, Complement inhibitor (63%)63% related to the paper, Microangiopathic hemolytic anemia (61%)61% related to the paper
View PDF
48 Citations
open accessOpen access Journal Article DOI: 10.4081/HR.2009.E4
Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
Zhenshu Xu1, Shundong Cang1, Ting Yang2, Delong Liu1
13 Mar 2009 - Hematology Reviews

Abstract:

Emerging evidence suggests that the three tyrosine kinase inhibitors currently approved for the treatment of patients with chronic myelogenous leukemia (CML) – imatinib, dasatinib, and nilotinib – have potential cardiotoxic effects. The mechanisms behind these events, and the relations between them, are largely unclear. For e... Emerging evidence suggests that the three tyrosine kinase inhibitors currently approved for the treatment of patients with chronic myelogenous leukemia (CML) – imatinib, dasatinib, and nilotinib – have potential cardiotoxic effects. The mechanisms behind these events, and the relations between them, are largely unclear. For example, relative to dasatinib and nilotinib, severe congestive heart failure and left ventricular dysfunction are rare but prominent with imatinib treatment, particularly in patients receiving higher doses (>600 mg/day). In comparison with imatinib, prolongation of the QT interval is relatively common in patients treated with either dasatinib or nilotinib. In contrast to nilotinib, pericardial effusions are observed with both imatinib and dasatinib. It is suggested that these data, an evaluation of cardiac status, use of concomitant medications, and potential risk factors should be considered in the management of CML. read more read less

Topics:

Nilotinib (79%)79% related to the paper, Dasatinib (69%)69% related to the paper, Chronic myelogenous leukemia (59%)59% related to the paper, Imatinib (59%)59% related to the paper, Tyrosine kinase (57%)57% related to the paper
View PDF
42 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Hematology Reports .

It automatically formats your research paper to PagePress Publications formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Hematology Reports format uses Vancouver citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Hematology Reports in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Hematology Reports guidelines and auto format it.

2. Do you follow the Hematology Reports guidelines?

Yes, the template is compliant with the Hematology Reports guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Hematology Reports ?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Hematology Reports citation style.

4. Can I use the Hematology Reports templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Hematology Reports .

5. Can I use a manuscript in Hematology Reports that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Hematology Reports that you can download at the end.

6. How long does it usually take you to format my papers in Hematology Reports ?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Hematology Reports .

7. Where can I find the template for the Hematology Reports ?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Hematology Reports 's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Hematology Reports 's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Hematology Reports an online tool or is there a desktop version?

SciSpace's Hematology Reports is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Hematology Reports ?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Hematology Reports ?”

11. What is the output that I would get after using Hematology Reports ?

After writing your paper autoformatting in Hematology Reports , you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Hematology Reports 's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Hematology Reports ?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Hematology Reports . The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Hematology Reports ?

The 5 most common citation types in order of usage for Hematology Reports are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Hematology Reports ?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Hematology Reports 's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Hematology Reports in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Hematology Reports Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Hematology Reports formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template